Research

Hormonal

Medicare-aged adults (65-69) with obesity but without Type 2 Diabetes have significantly lower prescribing and dispensing rates of anti-obesity GLP-1 receptor agonists compared to adults aged 60-64, likely due to Medicare's prohibition on covering these medications.

If you are over 65 and have obesity but no diabetes, you may face significant barriers to accessing GLP-1 medications like Wegovy or Zepbound because Medicare currently prohibits coverage for these specific anti-obesity drugs. This results in significantly lower prescribing and filling rates compared to those aged 60-64. Consult your provider about available options, but be aware that cost and coverage restrictions may limit your access to these specific hormonal treatments.

ModerateSupportsMEDIUM confidence
Prescribing and initiation of AOM GLP-1 RA are lower for Medicare-aged adults, which may be due to a lack of coverage. Medicare coverage of AOM GLP-1 RA has the potential to increase prescribing and initiation substantially.
Patricia J Rodriguez et al. · medRxiv · 2024

Why this rating

Observational cohort study using real-world data; not a randomized controlled trial, but large sample size (n=413,833).

Source

Access to Anti-Obesity GLP-1s for Medicare-Aged Adults

Patricia J Rodriguez et al. · medRxiv · 2024

DOI 10.1101/2024.03.26.24304923

preprint · n=413833
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →